Overview

To Demonstrate the Relative Bioequivalence of Lisinopril 1 x 40 mg Tablets Under Fasting Conditions

Status:
Completed
Trial end date:
2000-04-01
Target enrollment:
Participant gender:
Summary
To Demonstrate the Relative Bioequivalence of Lisinopril 1 x 40 mg Tablets Under Fasting Conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Sandoz
Treatments:
Lisinopril